Biocryst Pharmaceuticals (BCRX) Gross Profit (2010 - 2026)

Biocryst Pharmaceuticals has reported Gross Profit for 16 years, with the latest figure at $151.0 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 7.14% year-over-year to $151.0 million; the trailing twelve-month figure through Mar 2026 stood at $460.0 million (down 5.72% YoY), and the FY2025 full-year result was $855.8 million, up 95.18% from the prior year.
• Gross Profit for Q1 2026 stood at $151.0 million, up from -$8.8 million in the prior quarter.
• The five-year high for Gross Profit was $160.6 million in Q2 2025, with the low at -$8.8 million in Q4 2025.
• Historically, Gross Profit has averaged $95.9 million across 5 years, with a median of $91.5 million in 2024.
• Annual changes were most pronounced in 2022 — Gross Profit soared 278.25% — and 2025, when it sank 107.03%.
• Biocryst Pharmaceuticals' Gross Profit stood at $77.2 million in 2022, then increased by 19.03% to $91.8 million in 2023, then jumped by 36.58% to $125.4 million in 2024, then plunged by 107.03% to -$8.8 million in 2025, then soared by 1813.59% to $151.0 million in 2026.
• The last three Gross Profit figures came in at $151.0 million (Q1 2026), -$8.8 million (Q4 2025), and $157.2 million (Q3 2025), per Business Quant data.